Dapagliflozin in Elderly Care

• DOI: 10.4103/jiag.jiag_61_24
• Publication Date: 2025-04-16T17:00:15Z
• Authors: Sameer Angurana; Kiranpreet Kaur; Baldeep Kaur; Ashish Goel
• Keywords: Dapagliflozin

Abstract The sodium-glucose co-transporter 2 inhibitor dapagliflozin functions as a vital pharmacological treatment for type diabetes mellitus (T2DM). medication works through distinct mechanism that does not depend on insulin production while simultaneously helping patients lose weight and manage blood pressure reducing their risk of heart failure chronic kidney disease thus making it an essential modern healthcare practice. It demonstrates beneficial effects cardiovascular health renal parameters, although the precise mechanisms contributing to these advantages remain subject ongoing research. This review seeks explain current status drug regarding its impact outcomes well decreasing mortality rates among individuals diagnosed with T2DM. also evaluates efficacy, safety, special considerations use in geriatric population, highlighting unique benefits potential risks this age group.